Today

the U.S. Supreme Court invalidated patents on two genes associated with hereditary breast and ovarian cancer – BRCA1 and BRCA2 - in response to a lawsuit filed by the ACLU and the Public Patent Foundation. This is a MAJOR victor for patients and the medical and scientific communities.